BridgeBio Oncology Therapeutics (BBOT) Other Non Operating Income (2025 - 2026)
BridgeBio Oncology Therapeutics (BBOT) posted Other Non Operating Income of -$94000.0 for Q1 2026, down 1075.0% sequentially from -$8000.0 in Q4 2025, and down 4600.0% YoY from $2088.9 in Q1 2025.
BridgeBio Oncology Therapeutics (BBOT) Other Non Operating Income (2025 - 2026) Analysis & Trends
BridgeBio Oncology Therapeutics has reported Other Non Operating Income for 2 years, with the latest figure at -$94000.0 in Q1 2026.
- Quarterly Other Non Operating Income fell 4600.0% year-over-year to -$94000.0 in Q1 2026, while the trailing twelve-month figure through Mar 2026 was -$134000.0 (changed N/A YoY) and the FY2025 annual result came in at -$35000.0, changed N/A from the prior year.
- Other Non Operating Income slipped to -$94000.0 in Q1 2026 per BBOT's latest filing, from -$8000.0 in the prior quarter.
- Over five years, Other Non Operating Income peaked at -$2000.0 in Q1 2025 and troughed at -$94000.0 in Q1 2026.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) |
|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 128.13 Bn | 120.28 Bn | 2.84 Bn |
| 2 | Regeneron Pharmaceuticals | 112.33 Bn | 104.33 Bn | 3.93 Bn |
| 3 | Argenx Se | 53.24 Bn | 48.05 Bn | 1.41 Bn |
| 4 | Revolution Medicines | 43.64 Bn | 43.64 Bn | - |
| 5 | BeOne Medicines | 39.27 Bn | 34.17 Bn | 1.53 Bn |
| 6 | MindWalk Holdings | 35.32 Bn | 35.31 Bn | 1.82 Bn |
| 7 | Royalty Pharma | 33.72 Bn | 35.84 Bn | - |
| 8 | Alnylam Pharmaceuticals | 30.58 Bn | 27.27 Bn | 992.69 Mn |
| 9 | Insmed | 27.01 Bn | 25.85 Bn | 358.27 Mn |
| 10 | BridgeBio Oncology Therapeutics | 726.38 Mn | 500.67 Mn | - |
Historic Data
Download Data| Date | Value |
|---|---|
| Jun 30, 2026 | -14,000.00 |
| Mar 31, 2026 | -94,000.00 |
| Dec 31, 2025 | -8,000.00 |
| Sep 30, 2025 | -30,000.00 |
| Mar 31, 2025 | -2,000.00 |